A placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2 diabetes inadequately controlled by diet and exercise only or with metformin or sulfonylurea monotherapy.

Trial Profile

A placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2 diabetes inadequately controlled by diet and exercise only or with metformin or sulfonylurea monotherapy.

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 23 Apr 2010

At a glance

  • Drugs Ibipinabant (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Apr 2010 Trial sponsor, affiliate changed from Solvay Pharmaceuticals to abbott labas reported by ClinicalTrials.gov.
    • 08 Jan 2008 Status changed from initiated to withdrawn prior to recruitment.
    • 19 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top